By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Data detailed on Biotechnology have been presented. According to news reporting originating in Seoul, South Korea, by NewsRx journalists, research stated, "Since the concept of reprogramming mature somatic cells to generate induced pluripotent stem cells (iPSCs) was demonstrated in 2006, iPSCs have become a potential substitute for embryonic stem cells (ESCs) given their pluripotency and 'stemness' characteristics, which resemble those of ESCs. We investigated to reprogram fibroblast-like synoviocytes (FLSs) from patients with rheumatoid arthritis (RA) and osteoarthritis (OA) to generate iPSCs using a 4-in-1 lentiviral vector system."
The news reporters obtained a quote from the research from the Catholic University of Korea, "A 4-in-1 lentiviral vector containing Oct4, Sox2, Klf4, and c-Myc was transduced into RA and OA FLSs isolated from the synovia of two RA patients and two OA patients. Immunohistochemical staining and real-time PCR studies were performed to demonstrate the pluripotency of iPSCs. Chromosomal abnormalities were determined based on the karyotype. SCID-beige mice were injected with iPSCs and sacrificed to test for teratoma formation. After 14 days of transduction using the 4-in-1 lentiviral vector, RA FLSs and OA FLSs were transformed into spherical shapes that resembled embryonic stem cell colonies. Colonies were picked and cultivated on matrigel plates to produce iPSC lines. Real-time PCR of RA and OA iPSCs detected positive markers of pluripotency. Immunohistochemical staining tests with Nanog, Oct4, Sox2, Tra-1-80, Tra-1-60, and SSEA-4 were also positive. Teratomas that comprised three compartments of ectoderm, mesoderm, and endoderm were formed at the injection sites of iPSCs. Established iPSCs were shown to be compatible by karyotyping. Finally, we confirmed that the patient-derived iPSCs were able to differentiate into osteoblast, which was shown by an osteoimage mineralization assay. FLSs derived from RA and OA could be cell resources for iPSC reprogramming."
According to the news reporters, the research concluded: "Disease-and patient-specific iPSCs have the potential to be applied in clinical settings as source materials for molecular diagnosis and regenerative therapy."
For more information on this research see: Generation of disease-specific induced pluripotent stem cells from patients with rheumatoid arthritis and osteoarthritis. Arthritis Research & Therapy, 2014;16(1):429-436. Arthritis Research & Therapy can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; Arthritis Research & Therapy - arthritis-research.com/)
Our news correspondents report that additional information may be obtained by contacting J. Lee, Catholic University of Korea, Dept. of Lab Med, Coll Med, Catholic Genet Lab CenterSeoul St Marys Hosp, Seoul 137701, South Korea. Additional authors for this research include Y. Kim, H. Yi, S. Diecke, J. Kim, H. Jung, Y.A. Rim, S.M. Jung, M. Kim, Y.G. Kim, S.H. Park, H.Y. Kim and J.H. Ju (see also Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Seoul, Genetics, South Korea, Gene Therapy, Bioengineering, Joint Diseases, Osteoarthritis, Adult Stem Cells, Rheumatic Diseases, Stem Cell Research, Rheumatoid Arthritis, Musculoskeletal Diseases, Induced Pluripotent Stem Cells
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC